Insulin vs LL-37
Overview
Insulin is primarily a weight management & metabolic peptide, while LL-37 is used for immune support.
This page compares Insulin and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Insulin | LL-37 | |
|---|---|---|
| Category | Weight Management & Metabolic | Immune Support |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets | 2-5 mg |
| Frequency | Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin | twice weekly |
| Reported benefits | Glycemic control, prevention of diabetic ketoacidosis, reduction of microvascular complications (retinopathy, nephropathy, neuropathy), life-sustaining therapy in type 1 diabetes, HbA1c reduction in type 2 diabetes | Antimicrobial activity, immune modulation, wound healing, anti-inflammatory |
| Reported side effects | Hypoglycemia, weight gain, injection-site lipohypertrophy, rare hypersensitivity reactions, peripheral edema at initiation | Generally safe, minimal side effects |
Key differences
Primary use. Insulin is categorised under Weight Management & Metabolic, while LL-37 falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Insulin: FDA-approved. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Insulin is typically dosed at Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets (Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin). LL-37 is typically dosed at 2-5 mg (twice weekly).
Can you stack them?
Some protocols combine peptides, but stacking Insulin and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Insulin and LL-37?
- Insulin is primarily a weight management & metabolic peptide, while LL-37 is used for immune support. Insulin is FDA-approved for one or more indications, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Insulin used for?
- The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus.
- What is LL-37 used for?
- Antimicrobial defense peptide.
- Can you take Insulin and LL-37 together?
- Some users combine peptides within a single protocol, but stacking Insulin and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Insulin or LL-37 FDA-approved?
- Insulin is FDA-approved for one or more indications. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).